Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults

Molecular Therapy Methods and Clinical Development

Volumn 3, Issue , 2016, Pages 16061-

  Mutua, Gaudensia ^a   Farah, Bashir ^a   Langat, Robert ^a   Indangasi, Jackton ^a   Ogola, Simon ^a   Onsembe, Brian ^a   Kopycinski, Jakub T ^b   Hayes, Peter ^b   Borthwick, Nicola J ^c   Ashraf, Ambreen ^b   Dally, Len ^d   Barin, Burc ^d   Tillander, Annika ^f   Gilmour, Jill ^b   De Bont, Jan ^b   Crook, Alison ^c   Hannaman, Drew ^e   Cox, Josephine H ^b   Anzala, Omu ^a   Fast, Patricia E ^b   Reilly, Marie ^f   Chinyenze, Kundai ^b   Jaoko, Walter ^a   Hanke, Tomáš ^c,g   more..

^a UNIVERSITY OF NAIROBI   (Kenya)

^b INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^c NIHR Biomedical Researcg Centre   (United Kingdom)

^d EMMES CORPORATION   (United States)

^e Ichor Medical Systems Inc   (United States)

^f KAROLINSKA INSTITUTE   (Sweden)

^g KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROTEOME; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICA SOUTH OF THE SAHARA; AFRICAN; ARTICLE; CD8+ T LYMPHOCYTE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; INFECTION PREVENTION; MALE; POXVIRIDAE; PRIORITY JOURNAL; RISK; SIMIAN VIRUS; VACCINIA VIRUS; VIRUS INHIBITION; VIRUS REPLICATION; AFRICA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEVER; HEADACHE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALAISE; MYALGIA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VACCINE IMMUNOGENICITY;

EID: 85015188779     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2016.61     Document Type: Article

References (78)

1. 1 UNAIDS (2015), Aids by the Numbers. http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2015/JC2571_AIDS_by_the_numbers_en.pdf.
2. 2 Haynes, BF, Shaw, GM, Korber, B, Kelsoe, G, Sodroski, J, Hahn, BH, et al. HIV-host interactions: Implications for vaccine design. Cell Host Microbe 19 (2016), 292–303.
3. 3 Walker, B, McMichael, A, The T-cell response to HIV. Cold Spring Harb Perspect Med, 2, 2012 pii: a007054. doi: 10.1101/cshperspect.a007054. Review. PMID: 23002014.
4. 4 Walker, BD, Burton, DR, Toward an AIDS vaccine. Science 320 (2008), 760–764.
5. 5 Hansen, SG, Ford, JC, Lewis, MS, Ventura, AB, Hughes, CM, Coyne-Johnson, L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473 (2011), 523–527.
6. 6 Hansen, SG, Piatak, M Jr, Ventura, AB, Hughes, CM, Gilbride, RM, Ford, JC, et al. Immune clearance of highly pathogenic SIV infection. Nature 502 (2013), 100–104.
7. 7 Hansen, SG, Sacha, JB, Hughes, CM, Ford, JC, Burwitz, BJ, Scholz, I, et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science, 340, 2013, 1237874.
8. 8 Hansen, SG, Wu, HL, Burwitz, BJ, Hughes, CM, Hammond, KB, Ventura, AB, et al. Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E. Science 351 (2016), 714–720.
9. 9 Freel, SA, Picking, RA, Ferrari, G, Ding, H, Ochsenbauer, C, Kappes, JC, et al. Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. J Virol 86 (2012), 6835–6846.
10. 10 Goonetilleke, N, Liu, MK, Salazar-Gonzalez, JF, Ferrari, G, Giorgi, E, Ganusov, VV, et al., CHAVI Clinical Core B, The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 206 (2009), 1253–1272.
11. 11 Fellay, J, Shianna, KV, Ge, D, Colombo, S, Ledergerber, B, Weale, M, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 317 (2007), 944–947.
12. 12 Lee, JK, Stewart-Jones, G, Dong, T, Harlos, K, Di Gleria, K, Dorrell, L, et al. T cell cross-reactivity and conformational changes during TCR engagement. J Exp Med 200 (2004), 1455–1466.
13. 13 Almeida, JR, Price, DA, Papagno, L, Arkoub, ZA, Sauce, D, Bornstein, E, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204 (2007), 2473–2485.
14. 14 Migueles, SA, Laborico, AC, Shupert, WL, Sabbaghian, MS, Rabin, R, Hallahan, CW, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 3 (2002), 1061–1068.
15. 15 Betts, MR, Nason, MC, West, SM, De Rosa, SC, Migueles, SA, Abraham, J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107 (2006), 4781–4789.
16. 16 Eller, MA, Goonetilleke, N, Tassaneetrithep, B, Eller, LA, Costanzo, MC, Johnson, S, et al. Expansion of inefficient HIV-specific CD8 T cells during acute infection. J Virol 90 (2016), 4005–4016.
17. 17 Price, DA, Asher, TE, Wilson, NA, Nason, MC, Brenchley, JM, Metzler, IS, et al. Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. J Exp Med 206 (2009), 923–936.
18. 18 Altfeld, M, Allen, TM, Hitting HIV where it hurts: an alternative approach to HIV vaccine design. Trends Immunol 27 (2006), 504–510.
19. 19 Hancock, G, Yang, H, Yorke, E, Wainwright, E, Bourne, V, Frisbee, A, et al. Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. PLoS Pathog, 11, 2015, e1004658.
20. 20 Hanke, T, Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines. Expert Opin Biol Ther 14 (2014), 601–616.
21. 21 Létourneau, S, Im, EJ, Mashishi, T, Brereton, C, Bridgeman, A, Yang, H, et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One, 2, 2007, e984.
22. 22 Mothe, B, Llano, A, Ibarrondo, J, Daniels, M, Miranda, C, Zamarreño, J, et al. Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med, 9, 2011, 208.
23. 23 Murakoshi, H, Akahoshi, T, Koyanagi, M, Chikata, T, Naruto, T, Maruyama, R, et al. Clinical control of HIV-1 by cytotoxic T cells specific for multiple conserved epitopes. J Virol 89 (2015), 5330–5339.
24. 24 Rolland, M, Nickle, DC, Mullins, JI, HIV-1 group M conserved elements vaccine. PLoS Pathog, 3, 2007, e157.
25. 25 Kiepiela, P, Ngumbela, K, Thobakgale, C, Ramduth, D, Honeyborne, I, Moodley, E, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13 (2007), 46–53.
26. 26 Rolland, M, Heckerman, D, Deng, W, Rousseau, CM, Coovadia, H, Bishop, K, et al. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One, 3, 2008, e1424.
27. 27 Ahmed, T, Borthwick, NJ, Gilmour, J, Hayes, P, Dorrell, L, Hanke, T, Control of HIV-1 replication in vitro by vaccine-induced human CD8(+) T cells through conserved subdominant Pol epitopes. Vaccine 34 (2016), 1215–1224.
28. 28 Borthwick, N, Ahmed, T, Ondondo, B, Hayes, P, Rose, A, Ebrahimsa, U, et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 22 (2014), 464–475.
29. 29 Fujiwara, M, Takiguchi, M, HIV-1-specific CTLs effectively suppress replication of HIV-1 in HIV-1-infected macrophages. Blood 109 (2007), 4832–4838.
30. 30 Hayes, PJ, Cox, JH, Coleman, AR, Fernandez, N, Bergin, PJ, Kopycinski, JT, et al. Adenovirus based Hiv-1 vaccine candidates tested in efficacy trials elicit Cd8 T-cells with limited breadth of Hiv-1 inhibition. AIDS, 2016 (in press).
31. 31 Naarding, MA, Fernandez, N, Kappes, JC, Hayes, P, Ahmed, T, Icyuz, M, et al. Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses. J Immunol Methods 409 (2014), 161–173.
32. 32 Sáez-Cirión, A, Lacabaratz, C, Lambotte, O, Versmisse, P, Urrutia, A, Boufassa, F, et al., Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group, HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 104 (2007), 6776–6781.
33. 33 Sáez-Cirión, A, Sinet, M, Shin, SY, Urrutia, A, Versmisse, P, Lacabaratz, C, et al., ANRS EP36 HIV Controllers Study Group, Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol 182 (2009), 7828–7837.
34. 34 Spentzou, A, Bergin, P, Gill, D, Cheeseman, H, Ashraf, A, Kaltsidis, H, et al. Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J Infect Dis 201 (2010), 720–729.
35. 35 Yang, H, Wu, H, Hancock, G, Clutton, G, Sande, N, Xu, X, et al. Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J Infect Dis 206 (2012), 552–561.
36. 36 Yang, OO, Will we be able to ‘spot’ an effective HIV-1 vaccine?. Trends Immunol 24 (2003), 67–72.
37. 37 Fischer, W, Perkins, S, Theiler, J, Bhattacharya, T, Yusim, K, Funkhouser, R, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13 (2007), 100–106.
38. 38 Mothe, B, Hu, X, Llano, A, Rosati, M, Olvera, A, Kulkarni, V, et al. A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. J Transl Med, 13, 2015, 60.
39. 39 Ondondo, B, Murakoshi, H, Clutton, G, Abdul-Jawad, S, Wee, EG, Gatanaga, H, et al. Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage is recognized by protective responses in untreated infection. Mol Ther 24 (2016), 832–842.
40. 40 Goulder, PJ, Walker, BD, HIV and HLA class I: an evolving relationship. Immunity 37 (2012), 426–440.
41. 41 Migueles, SA, Connors, M, Success and failure of the cellular immune response against HIV-1. Nat Immunol 16 (2015), 563–570.
42. 42 Yue, L, Pfafferott, KJ, Baalwa, J, Conrod, K, Dong, CC, Chui, C, et al. Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients. PLoS Pathog, 11, 2015, e1004565.
43. 43 Carlson, JM, Schaefer, M, Monaco, DC, Batorsky, R, Claiborne, DT, Prince, J, et al. HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. Science, 345, 2014, 1254031.
44. 44 Claiborne, DT, Prince, JL, Scully, E, Macharia, G, Micci, L, Lawson, B, et al. Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression. Proc Natl Acad Sci USA 112 (2015), E1480–E1489.
45. 45 Deng, K, Pertea, M, Rongvaux, A, Wang, L, Durand, CM, Ghiaur, G, et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517 (2015), 381–385.
46. 46 Ferguson, AL, Mann, JK, Omarjee, S, Ndung'u, T, Walker, BD, Chakraborty, AK, Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. Immunity 38 (2013), 606–617.
47. 47 Hertz, T, Ahmed, H, Friedrich, DP, Casimiro, DR, Self, SG, Corey, L, et al. HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. PLoS Pathog, 9, 2013, e1003404.
48. 48 Im, EJ, Hong, JP, Roshorm, Y, Bridgeman, A, Létourneau, S, Liljeström, P, et al. Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges. PLoS Pathog, 7, 2011, e1002041.
49. 49 Janes, H, Frahm, N, DeCamp, A, Rolland, M, Gabriel, E, Wolfson, J, et al. MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load. PLoS One, 7, 2012, e43396.
50. 50 Li, F, Finnefrock, AC, Dubey, SA, Korber, BT, Szinger, J, Cole, S, et al. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLoS One, 6, 2011, e20479.
51. 51 Liu, MK, Hawkins, N, Ritchie, AJ, Ganusov, VV, Whale, V, Brackenridge, S, et al., CHAVI Core B, Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest 123 (2013), 380–393.
52. 52 Barouch, DH, Stephenson, KE, Borducchi, EN, Smith, K, Stanley, K, McNally, AG, et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155 (2013), 531–539.
53. 53 Santra, S, Muldoon, M, Watson, S, Buzby, A, Balachandran, H, Carlson, KR, et al. Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology 428 (2012), 121–127.
54. 54 McMichael, AJ, Koff, WC, Vaccines that stimulate T cell immunity to HIV-1: the next step. Nat Immunol 15 (2014), 319–322.
55. 55 Mpendo, J, Mutua, G, Nyombayire, J, Ingabire, R, Nanvubya, A, Anzala, O, et al. A phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of electroporated HIV DNA with or without interleukin 12 in prime-boost combinations with an Ad35 HIV vaccine in healthy HIV-seronegative African adults. PLoS One, 10, 2015, e0134287.
56. 56 Omosa-Manyonyi, G, Mpendo, J, Ruzagira, E, Kilembe, W, Chomba, E, Roman, F, et al. A phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of an adjuvanted HIV-1 Gag-Pol-Nef fusion protein and adenovirus 35 Gag-RT-Int-Nef vaccine in healthy HIV-uninfected African adults. PLoS One, 10, 2015, e0125954.
57. 57 Sarkar, S, Teichgräber, V, Kalia, V, Polley, A, Masopust, D, Harrington, LE, et al. Strength of stimulus and clonal competition impact the rate of memory CD8 T cell differentiation. J Immunol 179 (2007), 6704–6714.
58. 58 Goonetilleke, N, Moore, S, Dally, L, Winstone, N, Mahmoud, N, Cebere, I, et al. Prime-boost vaccination with recombinant DNA and Mva expressing Hiv-1 clade a Gag and immunodominant Ctl epitopes induces multi-functional Hiv-1-specific T cells in healthy subjects. J Virol 80 (2006), 4717–4728.
59. 59 Mwau, M, Cebere, I, Sutton, J, Chikoti, P, Winstone, N, Wee, EG, et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85:Pt 4 (2004), 911–919.
60. 60 Abdul-Jawad, S, Ondondo, B, van Hateren, A, Gardner, A, Elliott, T, Korber, B, et al. Increased valency of conserved-mosaic vaccines enhances the breadth and depth of epitope recognition. Mol Ther 24 (2016), 375–384.
61. 61 Catanzaro, AT, Koup, RA, Roederer, M, Bailer, RT, Enama, ME, Moodie, Z, et al., Vaccine Research Center 006 Study Team, Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194 (2006), 1638–1649.
62. 62 Cebere, I, Dorrell, L, McShane, H, Simmons, A, McCormack, S, Schmidt, C, et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24 (2006), 417–425.
63. 63 Currier, JR, Ngauy, V, de Souza, MS, Ratto-Kim, S, Cox, JH, Polonis, VR, et al. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One, 5, 2010, e13983.
64. 64 Gilbert, PB, Chiu, YL, Allen, M, Lawrence, DN, Chapdu, C, Israel, H, et al., NIAID HIV Vaccine Trials Network, Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine 21 (2003), 2933–2947.
65. 65 Graham, BS, Koup, RA, Roederer, M, Bailer, RT, Enama, ME, Moodie, Z, et al., Vaccine Research Center 004 Study Team, Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194 (2006), 1650–1660.
66. 66 Hayton, EJ, Rose, A, Ibrahimsa, U, Del Sorbo, M, Capone, S, Crook, A, et al. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS One, 9, 2014, e101591.
67. 67 McCormack, S, Stöhr, W, Barber, T, Bart, PA, Harari, A, Moog, C, et al. EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 26 (2008), 3162–3174.
68. 68 Sheehy, SH, Duncan, CJ, Elias, SC, Biswas, S, Collins, KA, O'Hara, GA, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One, 7, 2012, e31208.
69. 69 Tacket, CO, Roy, MJ, Widera, G, Swain, WF, Broome, S, Edelman, R, Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 17 (1999), 2826–2829.
70. 70 McElrath, MJ, De Rosa, SC, Moodie, Z, Dubey, S, Kierstead, L, Janes, H, et al., Step Study Protocol Team, HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis. Lancet 372 (2008), 1894–1905.
71. 71 Catanzaro, AT, Roederer, M, Koup, RA, Bailer, RT, Enama, ME, Nason, MC, et al., VRC 007 Study Team, Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25 (2007), 4085–4092.
72. 72 Churchyard, GJ, Morgan, C, Adams, E, Hural, J, Graham, BS, Moodie, Z, et al., NIAID HIV Vaccine Trials Network, A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One, 6, 2011, e21225.
73. 73 Rerks-Ngarm, S, Pitisuttithum, P, Nitayaphan, S, Kaewkungwal, J, Chiu, J, Paris, R, et al., MOPH-TAVEG Investigators, Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361 (2009), 2209–2220.
74. 74 Heller, LC, Heller, R, Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 10 (2010), 312–317.
75. 75 Kalams, SA, Parker, SD, Elizaga, M, Metch, B, Edupuganti, S, Hural, J, et al., NIAID HIV Vaccine Trials Network, Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 208 (2013), 818–829.
76. 76 Low, L, Mander, A, McCann, K, Dearnaley, D, Tjelle, T, Mathiesen, I, et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 20 (2009), 1269–1278.
77. 77 Vasan, S, Hurley, A, Schlesinger, SJ, Hannaman, D, Gardiner, DF, Dugin, DP, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One, 6, 2011, e19252.
78. 78 Freel, SA, Lamoreaux, L, Chattopadhyay, PK, Saunders, K, Zarkowsky, D, Overman, RG, et al. Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol 84 (2010), 4998–5006.